用於治療膀胱原位扁平泌尿上皮癌，亦作為僅限於膀胱黏膜層(Ta 期或 T1 期)的原發性或復發 性之表淺型非侵犯性乳突狀腫瘤於經尿道膀胱腫瘤刮除手術(TURBT)後之輔助性治療。

Antineoplastic Agent, Biological Response Modulator

Hypersensitivity to impaired immune response; positive HIV serology; pregnancy and lactation; positive tuberculin reaction in conjunction with clinical evidence of existing active tuberculosis; urinary tract infections; trauma to urinary bladder; fever; treatment with antitubercular agents.

BCG (intravesical) is not recommended for use during pregnancy.

Frequency, urgency of micturition and dysuria:
these symptoms usually occur from 2nd or 3rd instillation onwards.
Cystitis and typical granulomatous inflammatory reactions which occur in the mucosa of urinary bladder:
the symptoms usually disappear within 2 days and do not require treatment. Cystitis may be more prolonged during maintenance treatment and if severe, Isoniazid 300 mg daily can be given with analgesics until symptoms disappear.
Malaise and low-medium grade fever and/or a flu like syndrome:
these symptoms usually occur in 4 hours after instillation and disappear within 24 – 48 hours.

Bladder cancer: Intravesicular: treatment should be started 2-3 weeks after performing TURBT. The treatment schedule is weekly repeated instillation with SII-ONCO-BCG (120 mg) during first 6 weeks, followed by 3 consecutive weekly instillations at 3 months, at 6 months and thereafter every 6 months upto 36 months.